Collectively, the above studies indicate that ERK5 may reduce the burden of ROS that would result in the death of leukaemia cells, and ERK5-dependent antioxidant responses may prevent additional ROS-mediated mutagenesis that could support leukaemia progression. This evidence concerns the gene MAPK7 and leukemia.